SEC filings
Vertex Pharmaceuticals (VRTX)
Recent filings Vertex Pharmaceuticals made with the SEC, newest first. Most have a short AI-generated summary, and every one links to the original.
CIK 0000875320All filings on SEC.gov
10-QQuarterly report
Quarterly report
Vertex Pharmaceuticals reported third-quarter 2026 total revenues of $3.4 billion, up from $3.1 billion in the third quarter of 2025, and completed its acquisition of Crinetics Pharmaceuticals. …
8-KCurrent report
Results of Operations and Financial Condition
Vertex Pharmaceuticals reported third-quarter 2026 total revenue of $3.44 billion, up 12% year over year, and raised its full-year 2026 revenue guidance to $13.15 billion to $13.25 billion, citing CF therapies, CASGEVY, JOURNAVX, and the…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Vertex Pharmaceuticals appointed Daniel Brennan to its board of directors on October 20, 2026, increasing the board from ten to eleven members; Brennan also joined the Audit and Finance Committee and received a $400,000 restricted stock…
8-KCurrent report
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer effective January 1, 2027, at which point Charles F. Wagner, Jr. …
10-QQuarterly report
Quarterly report
Vertex Pharmaceuticals reported second-quarter 2026 total revenues of $3.3 billion, up from $3.0 billion in the same quarter of 2025, and disclosed a July agreement to acquire Crinetics Pharmaceuticals for $85.00 per share in cash, an…
8-KCurrent report
Results of Operations and Financial Condition
Vertex Pharmaceuticals reported second-quarter 2026 total revenue of $3.33 billion, up 12% from a year earlier, and raised its full-year 2026 revenue guidance to $13.1–13.2 billion from $12.95–13.1 billion. …
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.
Follow Vertex Pharmaceuticals in Readster
Add Vertex Pharmaceuticals to your watchlist and its SEC filings reach your brief alongside the news about it, every line cited to its source. Readster also follows topics, people, newsletters and podcasts.
No credit card. When the trial ends, you move to Readster Free unless you subscribe.